Characterization of ADAR, a key RNA editing protein with pro-viral activities

描述（由申请方提供）：干扰素（IFN）是由宿主细胞释放的一大类免疫调节蛋白。I型干扰素由于其对病毒感染的保护作用而引起广泛关注，并且它们也可用于治疗癌症、炎症性肠病和多发性硬化症。I型IFN与其受体的结合启动了诱导数百个IFN刺激基因（ISG）表达的信号级联，其中大多数尚未完全表征。Rice实验室先前的一项研究筛选了数百种ISG对不同病毒的抗病毒作用。从该筛选中，一种ISG，ADAR 1（作用于RNA 1的腺苷脱氨酶）--特别是同种型ADAR 1 p150--增强而不是抑制一组临床上重要的正链（+）RNA病毒的复制;西尼罗河病毒（WNV）、基孔肯雅病毒（CHIKV）、委内瑞拉马脑炎病毒（VEEV）和辛德毕斯病毒（SINV）. ADAR 1催化双链RNA（dsRNA）中腺苷（A）脱氨为肌苷（I），并且还作为dsRNA结合蛋白发挥功能，而不依赖于其编辑活性。我们的主要假设是ADAR 1 p150是A到I编辑病毒或宿主dsRNA，这导致（+）RNA病毒复制的增强。该提案的主要目标是了解ADAR 1 p150增强（+）RNA病毒复制的机制，并进一步确定宿主和病毒中ADAR 1 p150的RNA靶标。目的1提出通过突变ADAR 1 p150蛋白的不同结构域（包括负责RNA编辑的脱氨酶结构域）来确定ADAR 1 p150增强病毒复制的机制，以确定增强（+）RNA病毒复制所需的ADAR 1 p150结构域/活性。除了定义增强病毒复制所需的关键ADAR 1活动外，还将确定受影响的病毒生命周期步骤。目的2将通过在表达WT或突变型ADAR 1 p150的细胞中进行高通量RNA测序，进一步鉴定宿主和病毒中ADAR 1 p150“编辑”或“结合”的RNA序列。目前，对于SINV、WNV、CHIKV和VEEV没有可用的特异性治疗。此外，ADAR 1是人类免疫缺陷病毒（HIV）的前病毒ISG和丙型肝炎病毒（HCV）的抗病毒ISG，这两种全球流行病导致许多人死亡。因此，了解ADAR 1的机制和靶点的努力可能会导致新的治疗方法来对抗这些各种病毒感染。重要的是，小鼠中的ADAR 1缺失导致快速细胞凋亡、造血缺陷和IFN信号传导的整体上调，这导致胚胎致死。然而，我们仍然没有一个清晰的图片ADAR 1的作用机制和其在哺乳动物宿主中的特异性RNA靶点。因此，在未感染和病毒感染的细胞中检测ADAR 1的机制和靶点所获得的结果将作为理解阿达尔在宿主生物学中的作用的有价值的资源。

DESCRIPTION (provided by applicant): Interferons (IFNs) are a large class of immunomodulatory proteins released by host cells. Type I IFNs attract much attention due to their protective role against viral infections, and they may also be used to treat cancer, inflammatory bowel diseases, and multiple sclerosis. Binding of type I IFNs to its receptor initiates a signaling cascade that induces the expression of hundreds of IFN-stimulated genes (ISGs), the majority of which are not fully characterized. A previous study from the Rice lab screened hundreds of ISGs for antiviral effects on diverse viruses. From this screen one ISG, ADAR1 (adenosine deaminases acting on RNA 1) - specifically the isoform ADAR1p150 - enhanced rather than inhibited replication of a group of clinically important positive- strand (+)RNA viruses; West Nile virus (WNV), chikungunya virus (CHIKV), Venezuelan equine encephalitis virus (VEEV), and Sindbis virus (SINV). ADAR1 catalyzes deamination of adenosine (A) to inosine (I) in double-stranded RNA (dsRNA), and also functions as a dsRNA binding protein independent of its editing activity. Our primary hypothesis is that ADAR1p150 is A-to-I editing a virus or host dsRNA, which leads to the enhancement of (+)RNA virus replication. The main goal of this proposal is to understand the mechanism by which ADAR1p150 enhances (+)RNA virus replication, and to further identify RNA targets of ADAR1p150 in the host and virus. Aim 1 proposes to determine the mechanism by which ADAR1p150 enhances virus replication by mutating different domains of the ADAR1p150 protein - including its deaminase domain responsible for RNA editing - to determine the domains/activities of ADAR1p150 required to enhance (+)RNA virus replication. In addition to defining the critical ADAR1 activities required for enhanced virus replication, the affected virus lifecycle step(s) will be determined. Aim 2 will further identify RNA sequences 'edited by' or 'bound to' ADAR1p150 in the host and virus by performing high-throughput RNA-sequencing in cells expressing WT or mutant ADAR1p150. Currently there is no specific treatment available for SINV, WNV, CHIKV, and VEEV. Moreover, ADAR1 is a pro-viral ISG for human immunodeficiency virus (HIV), and an antiviral ISG for hepatitis C virus (HCV), two global pandemics that cause numerous human deaths. Thus, efforts to understand the mechanism and targets of ADAR1 may lead to new therapeutics to combat these various viral infections. Importantly, ADAR1 deletion in mice causes rapid apoptosis, defective hematopoiesis, and a global up-regulation in IFN signaling, which lead to embryonic lethality. However, we still do not have a clear picture of ADAR1 mechanism of action and its specific RNA targets in the mammalian host. Therefore, results gained from examining ADAR1 mechanism and targets in uninfected and virally infected cells will serve as a valuable resource to understand ADAR's roles in host biology.